Dietl, Barbara and Marienhagen, Jörg and Kühnel, Thomas and Schaefer, Christof and Kölbl, Oliver (2006) FDG-PET in radiotherapy treatment planning of advanced head and neck cancer--a prospective clinical analysis. Auris, nasus, larynx 33 (3), pp. 303-309.
Full text not available from this repository.
Other URL: http://dx.doi.org/10.1016/j.anl.2006.01.002
BACKGROUND: A prospective clinical analysis was carried out to assess the diagnostic and therapeutic impact of fluorodeoxyglucose positron emission tomography (FDG-PET) on planning radiotherapy in patients with advanced head and neck cancer in AJCC Stages III/IV. METHODS: From July 1999 to May 2004 FDG-PET was performed in 49 patients prior to radiotherapy for exclusion of systemic disease, synchronous second or unknown primary tumors. RESULTS: 45/49 (91.9%) FDG-PET findings could be confirmed in comparison with conventional imaging and the clinical follow up of 9.5 months. 21/49 FDG-PET (42.8%) yielded new diagnostic information with therapeutic implications in 20/49 (40.8%) cases. The therapy strategy was changed in 14/49 patients, minor modifications in the portal design occurred in 6/49 patients. 9/49 (18.3%) FDG-PET supported a curative strategy, 11/49 (22.4%) a palliative one. CONCLUSIONS: FDG-PET is a useful and important diagnostic tool mainly for exclusion of systemic disease in advanced head and neck cancer, thus influencing radiotherapy in 20/49 (40.8%) of patients investigated in our study.
|Institutions:|| Medicine > Lehrstuhl für Strahlentherapie|
Medicine > Lehrstuhl für Hals-Nasen-Ohren-Heilkunde
|Keywords:||FDG-PET; Diagnostic impact; Therapeutic impact; Head and neck cancer; Radiotherapy treatment planning|
|Subjects:||600 Technology > 610 Medical sciences Medicine|
|Refereed:||Yes, this version has been refereed|
|Created at the University of Regensburg:||Yes|
|Deposited On:||30 Aug 2007|
|Last Modified:||05 Aug 2009 13:35|